ad

Sarda Proteins Share Price in Focus After Q1 Results: Stages Turnaround With Rs 165.97 Lakh Profit on Solar Cell Pivot

Sarda Proteins Q1 FY27: net profit Rs 165.97 lakh, a turnaround from a year-ago loss. Revenue up 18.61% YoY to Rs 1,299.30 lakh on solar cell products pivot.


16 Jul 202611:19 am

Sarda Proteins Share Price in Focus After Q1 Results: Stages Turnaround With Rs 165.97 Lakh Profit on Solar Cell Pivot

Sarda Proteins share price was in focus on 16 July 2026 after the company staged a major financial turnaround in Q1 FY27, posting a net profit of Rs 165.97 lakh compared to a net loss in the corresponding quarter of the previous fiscal year.

Sarda Proteins, which has transitioned its business model to focus entirely on the renewable energy sector’s solar cell products segment, reported revenue from operations of Rs 1,299.30 lakh in Q1 FY27, an 18.61 percent year on year increase from Rs 1,095.46 lakh.

Click Here – Get Free Investment Predictions

Sarda Proteins Q1 FY27 Financial Highlights

Metric Q1 FY27 Q1 FY26 YoY Change
Revenue from Operations Rs 1,299.30 Lakh Rs 1,095.46 Lakh +18.61%
Net Profit / (Loss) Rs 165.97 Lakh Net Loss (Q1 FY26) Turnaround
EPS Rs 1.85 (Rs 2.86) Turned positive

The Sarda Proteins share price was closely watched on results day as the market weighed these Q1 FY27 numbers against expectations.

Sarda Proteins Q1 FY27 Performance Analysis

Univest is a SEBI-Registered Investment Advisor, Know More

Sarda Proteins’ financial turnaround follows a strategic pivot to a single-segment business model focused entirely on renewable energy sector solar cell products, a shift that has unlocked rapid commercial scaling, with core revenue jumping sequentially from a mere Rs 65.00 lakh in Q4 FY26 to Rs 1,299.30 lakh in Q1 FY27.

Other income also rose sharply to Rs 548.10 lakh from just Rs 0.08 lakh in the year-ago quarter, contributing to total revenue growth of 68.63 percent year on year to Rs 1,847.40 lakh, a factor investors should note when assessing the sustainability of this quarter’s core operating performance.

Basic and diluted earnings per share swung to a positive Rs 1.85 from a negative Rs 2.86 in Q1 FY26, while the company’s paid-up equity share capital also expanded significantly to Rs 89.759 lakh from Rs 17.259 lakh in the year-ago quarter, reflecting a capital raise alongside the business transformation.

This performance is the key data point behind the Sarda Proteins share price reaction, and it is the number analysts will build their FY27 estimates around going forward.

Key Business Factors in Q1 FY27

Solar Cell Business Pivot

This is a key factor behind the Sarda Proteins share price move on results day. The company’s strategic transition to a single-segment focus on renewable energy sector solar cell products has driven the sharp revenue and profit turnaround.

Sequential Revenue Scaling

This is a key factor behind the Sarda Proteins share price move on results day. Core revenue jumped from just Rs 65.00 lakh in Q4 FY26 to Rs 1,299.30 lakh in Q1 FY27, showing rapid commercial ramp-up of the new business.

Sharp Rise in Other Income

This is a key factor behind the Sarda Proteins share price move on results day. Other income rose to Rs 548.10 lakh from near-zero levels a year earlier, a factor that boosted total revenue but should be distinguished from core operating income.

Each of these factors fed into the Sarda Proteins share price move on results day, and together they frame how the market is likely to read the next quarter’s numbers as well.

Dividend Details

On the dividend front relevant to the Sarda Proteins share price story, sarda Proteins did not announce a dividend alongside its Q1 FY27 results, consistent with its recent transition to a new business segment.

FY27 Outlook

With Sarda Proteins now fully focused on the solar cell products segment and demonstrating rapid sequential revenue scaling, the company’s near-term trajectory will depend on whether this commercial ramp-up continues at pace, and whether core operating income, excluding the sharp rise in other income this quarter, shows sustained improvement in coming quarters.

Investors tracking the Sarda Proteins share price into the rest of FY27 should treat this outlook commentary as directional rather than guaranteed, and should watch subsequent quarterly filings to confirm whether the trajectory holds for the Sarda Proteins share price.

Sarda Proteins Stock Performance

Download the Univest iOS App or Univest Android App to track Sarda Proteins’s live share price and Q1 FY27 results reaction.

Sarda Proteins share price reflected renewed investor interest following the company’s financial turnaround and business transformation into the solar cell products segment. As of 16 July 2026, the stock was trading around Rs 97.78 on the BSE.

The Sarda Proteins share price chart over the next few sessions will help confirm whether the results-day move in the Sarda Proteins share price reflects a durable re-rating or a shorter-term reaction that partially fades as broader market flows take over.

Key Risks

New Business Execution Risk

This is a risk factor the Sarda Proteins share price could face ahead. As a company that has recently pivoted to an entirely new business segment, Sarda Proteins carries execution risk in scaling and sustaining its solar cell products operations.

Other Income Sustainability

This is a risk factor the Sarda Proteins share price could face ahead. A meaningful portion of this quarter’s total revenue growth came from other income, which may not recur at the same scale in future quarters.

Small-Cap Liquidity Risk

This is a risk factor the Sarda Proteins share price could face ahead. As a small-cap stock undergoing a business transformation, Sarda Proteins shares can see limited and volatile trading liquidity.

Any of these risks materialising could weigh on the Sarda Proteins share price in subsequent quarters, even after this quarter’s results-day reaction.

Conclusion

Sarda Proteins staged a major turnaround in Q1 FY27, swinging to a net profit of Rs 165.97 lakh on the back of its strategic pivot to solar cell products, with revenue up 18.61 percent year on year. Investors should track the sustainability of this commercial ramp-up and the composition of other income in coming quarters.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

FAQs

1. What was Sarda Proteins’ Q1 FY27 net profit?

Ans. Sarda Proteins reported a net profit of Rs 165.97 lakh in Q1 FY27, a turnaround from a net loss in the year-ago quarter.

2. What drove Sarda Proteins’ turnaround?

Ans. The company’s strategic pivot to a single-segment business model focused on renewable energy sector solar cell products drove the sharp revenue and profit turnaround.

3. What was Sarda Proteins’ Q1 FY27 revenue?

Ans. Revenue from operations grew 18.61 percent year on year to Rs 1,299.30 lakh in Q1 FY27.

4. Did Sarda Proteins declare a dividend with Q1 results?

Ans. No, Sarda Proteins did not announce a dividend alongside its Q1 FY27 results.

5. What is Sarda Proteins’ business now?

Ans. Sarda Proteins has transitioned to a single-segment business model focused entirely on the renewable energy sector’s solar cell products.

6. What is the Sarda Proteins share price today?

Ans. Sarda Proteins share price was trading around Rs 97.78 on the BSE as of 16 July 2026.

7. What was Sarda Proteins’ EPS in Q1 FY27?

Ans. Basic and diluted EPS turned positive at Rs 1.85 in Q1 FY27, up from a negative Rs 2.86 in Q1 FY26.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down